Arthritis Nursing CE Course for APRNs

ling or grating sensation in the joint when in use

hard, bony enlargement of the joint - phenomenon is more apparent in joints that are easily visualized, such as those of the fingers (Doherty & Abhishek, 2021)

If morning stiffness lasts more than 30 minutes, the patient should have a further evaluation for OA. The HCP may order serum blood tests to evaluate for an inflammatory process. Radiographs often serve as confirmatory agents. Joint space narrowing, subchondral sclerosis or cysts, formation of spikes on the tibial eminence, or visible osteophytes may be noted on the x-rays (Hoffman & Sullivan, 2020; Norris, 2020).

 

Treatment/Management

Nonpharmacological 

Caring for patients with OA requires a holistic approach to treatment and management. Patients may benefit from physical and occupational therapy to alleviate pain, improve functioning, and prevent further disability related to their OA. Exercise and muscle-strengthening activities are helpful to patients with OA. Warm and cold compress therapy may relieve pain. Patients may utilize assistive devices, such as a cane or walker, to help with mobility. If weight-bearing joints, such as the knees, are impacted, overweight patients may benefit from participating in a weight loss program. If nonpharmacological measures coupled with medications do not help the patient, surgical joint replacement, surgical fusions, arthroscopic irrigation, and debridement may be utilized (Hoffman & Sullivan, 2020; Norris, 2020).

 

Pharmacological 

Medication management for OA primarily focuses on pain management and reducing inflammation. Oral NSAIDs are considered first-line therapy to treat OA of any location. Examples of NSAIDs used for OA include ibuprofen (Advil, Motrin), naproxen (Aleve), and acetylsalicylic acid (ASA; Bayer Aspirin). NSAIDs work by inhibiting cyclooxygenase, thus preventing prostaglandin activity. Adverse effects include tinnitus, nausea, gastrointestinal (GI) bleeding, dyspepsia, occult bleeding, constipation, and abdominal bloating. NSAIDs should not be given if a patient has a history of GI bleeding or ulcers. To lessen the effects of NSAIDs on the GI tract, they should be administered with food or milk. NSAIDs are also contraindicated in patients with renal or hepatic insufficiency. The use of ASA (Bayer Aspirin) is contraindicated in children or adolescents with flu-like symptoms or a recent history of chickenpox infection due to the risk of Reye syndrome (Kolasinski et al., 2020; Woods, 2023). Dosing for the NSAIDs used to treat OA is as follows:

• ibuprofen (Advil, Motrin) 300 to 800 mg orally 3 to 4 times daily up to a maximum daily dose of 3.2 grams/day
• naproxen (Aleve) 250 to 500 mg orally twice daily; for extended-release (ER) tablets, dosing is 750 to 1,000 mg once daily; maximum dose of either formulation is 1,500 mg/day; treatment should not last longer than 6 months
• ASA (Bayer Aspirin) 3 grams/day orally divided into 4 to 6 doses; may increase the dose as needed with a target plasma salicylate level of 150 to 300 mcg/mL (Chou et al., 2011; Woods, 2023)

Patients with NSAID intolerance or contraindications may be given acetaminophen (Tylenol) for short-term treatment. Acetaminophen (Tylenol) combats prostaglandins from furthering inflammation. Dosing for adults and children over 12 years old is 650 to 1,000 mg in divided doses every 4 to 6 hours with a maximum dose of 4 grams/day. When used as a long-term treatment, the daily dose threshold should be reduced to 2.6 grams/day with close monitoring of hepatic function, electrolyte levels, and complete blood count (CBC). Adverse effects include nausea, vomiting, abdominal pain, leukopenia, neutropenia, anemia, jaundice, hypoglycemia, hypokalemia, tachycardia, and edema (peripheral and periorbital). Acetaminophen (Tylenol) can cause liver failure requiring a transplant or resulting in death; this level of hepatotoxicity is usually associated with doses larger than 4 grams/day. It is essential to educate patients on monitoring acetaminophen (Tylenol) intake as other over-the-counter medications may contain acetaminophen (Tylenol), which can increase the daily dose to toxic levels (Kolasinski et al., 2020; Woods, 2023)

If oral NSAIDs or acetaminophen (Tylenol) are ineffective in reducing pain, patients may be given an intraarticular (IA) corticosteroid injection. Corticosteroids decrease inflammation. Administering corticosteroids via IA injection into the hip joint should be performed using ultrasound guidance to ensure accurate placement. IA corticosteroids are also beneficial for patients with joint effusions. FDA-approved corticosteroids for IA injections include methylprednisolone acetate (Depo-Medrol), triamcinolone acetate (Zilretta), betamethasone acetate (Celestone Soluspan), and dexamethasone sodium phosphate (Hexadrol). The most common adverse effects include steroid-induced arthropathy, septic arthritis, synovitis, dermal or subcutaneous tissue atrophy, hypopigmentation, flushing of the face, neck, and torso, vasovagal response, and hyperglycemia (Shah et al., 2019). The recommended dosing of these agents is outlined below:

• methylprednisolone acetate (Depo-Medrol) dosing is dependent on which joint is being injected; for large joints, dosing is 20 to 80 mg; for medium joints, 10 to 40 mg; and for small joints, 4 to 10 mg; administration can be repeated every 1 to 5 weeks
• triamcinolone acetate (Zilretta) 32 mg administered as a single dose; repeat administration is not recommended
• betamethasone acetate (Celestone Soluspan) dosing is dependent on which joint is being injected; for very large joints, dosing is 6 to 12 mg; for large joints, 6 mg; for medium joints, 3 to 6 mg; and for small joints, 1.5 to 3 mg
• dexamethasone sodium phosphate (Hexadrol) 0.2 to 6 mg administered intraarticularly either as a one-time treatment or administered every 3 to 5 days up to every 2 to 3 weeks (Woods, 2023)

Duloxetine (Cymbalta) can also be used in patients with OA, of any joint, either as monotherapy or in combination with NSAIDs. Initial dosing is 30 mg orally once daily for 1 week, then increasing to 60 mg once daily as tolerated. Adverse reactions include fatigue, dizziness, headaches, suicidal thoughts, irritability, lethargy, blurred vision, constipation, dry mouth, nausea, dyspepsia, gastritis, vomiting, increased urinary frequency, delayed ejaculation or abnormal orgasm, weight gain, hypoglycemia, night sweats, and pruritus. Duloxetine (Cymbalta) is contraindicated in patients taking a monoamine oxidase inhibitor (MAOI). It should be used cautiously in patients with a history of mania, seizures, glaucoma, or hypertension or who drink alcohol regularly (Kolasinski et al., 2020; Woods, 2023).

Tramadol (Ultram) or other opioid medications can be used when NSAIDs are contraindicated, other treatment modalities have failed, or the patient is not a surgical candidate. Opioids are used as a last resort due to the risk of dependency and abuse and are not intended for chronic pain management. The initial dosing of immediate-release (IR) tramadol (Ultram) is 25 mg orally once daily in the morning, increasing by 25 mg every 3 days to 100 mg/day in four divided doses. If symptoms persist, the dose can be increased by 50 mg every 3 days to a maximum of 200 mg/day in four divided doses. Tramadol (Ultram) 50 mg to 100 mg every 4 to 6 hours as needed can also be added up to a maximum daily dose of 400 mg. When using ER tablets, the dosing is 100 mg orally once daily, increasing by 100 mg every 5 days to relieve symptoms up to a maximum dose of 300 mg/day. Adverse effects include dizziness, headaches, drowsiness, confusion, hypertension, peripheral edema, flushing, dry mouth, visual disturbances, nasal congestion, constipation, nausea, vomiting, dyspepsia, urinary frequency, urinary retention, hyperglycemia, and pruritus. Tramadol (Ultram) is contraindicated in patients with severe hepatic or renal impairment, current substance abuse, GI obstruction, or respiratory depression (Kolanski et al., 2020; Woods, 2023).

 

Rheumatoid Arthritis 

Pathophysiology

RA is an autoimmune disorder that prompts the immune system to react by causing inflammation in the synovial membrane; in turn, patients will feel joint stiffness and pain. The synovial membrane is treated as an invader by the immune system. This causes the activation of T-cells, the release of cytokines (including tumor necrosis factor [TNF] and interleukin-1), and the formation of antibodies. Genetically, individuals at greater risk of developing RA will express the human leukocyte antigen (HLA)-DRB1 gene, which can impact the immune response related to synovial inflammation. RA causes loss of the synovial fluid and calcification of the joint; over time, this causes a decrease in the range of motion. RA also has systemic bodily effects; it can damage the heart and vasculature, increasing the risk for myocardial infarctions (MIs) and cerebral vascular accidents (CVAs). In up to 80% of individuals, laboratory testing will confirm the presence of rheumatoid factor (RF) and autoantibodies in the serum (Hoffman & Sullivan, 2020; Norris, 2019; Scanlon & Sanders, 2019).

             Locally, the autoimmune response includes the activation of neutrophils, macrophages, and lymphocytes. The neutrophils and macrophages cause lysosomal enzymes to be released, which destroys the joint cartilage. The inflammation continues cyclically, eventually impacting the synovial cells and subsynovial tissues, causing hyperplasia and vasodilation. The vasodilation contributes to the redness and warmth and promotes increased capillary permeability causing edema. New vasculature is created and worsens inflammation by developing a pannus. The pannus, which is synovial tissue proliferation, destroys cartilage and bone; this contributes to the decreased range of motion and joint instability. Although patients may experience periods of exacerbation and remission, RA is a progressive and irreversible disease (Cajas et al., 2019; Norris, 2019).

 

Risk Factors/Protective Features

Currently, 1.5 million Americans have RA (Arthritis Foundation, 2021). Approximately 1% of individuals are diagnosed with RA (Hoffman & Sullivan, 2020). Genetics related to joint inflammation and over-activation of the immune system is correlated with a diagnosis of RA. Individuals with Pinna or Chippewa Indian heritage are at higher risk for developing RA. Adults in their 6^th decade are at the greatest risk for developing RA; women are at a 2 to 3 times greater risk for developing RA than men. Lifestyle factors, such as obesity and smoking, can increase an individual's risk of developing RA. Additional risks include having not given birth before, with the presence of HLA class II genotypes, and childhood exposure to second-hand smoke. Other environmental causative factors include exposure to viruses and bacteria in the gut. Patients may enter remission within a year of diagnosis; if not, they are more likely to experience disability within 10 years (Hinkle & Cheever, 2018; Hoffman & Sullivan, 2020; Norris, 2019).

 

Signs and Symptoms

While OA may have unilateral joint involvement, individuals with RA have bilateral joint involvement and disability. Joint stiffness can last 30 minutes to several hours; pain that prevents movement can later contribute to fibrosis (Hoffman & Sullivan, 2020). The most common sites of RA include the hands, wrists, knees, and ankles (Arthritis Foundation, 2021; CDC, 2020b; Norris, 2019). RA affects the smaller joints in the fingers, wrists, and ankles first (Arthritis Foundation, 2021). The hands may become deformed, and patients may exhibit swan-neck deformities and ulnar deviation due to edema, joint destruction, or subluxation (see Figure 3). In addition, patients may experience Heberden’s and Bouchard’s nodes in the fingers. Heberden’s nodes are swollen, hard, and painful distal interphalangeal (DIP) joints of the fingers. Bouchard’s nodes are similar but occur at the proximal interphalangeal (PIP) joint (see Figure 4). Over time, the cervical spine may become impacted. When the cervical spine is diseased with RA, patients may describe neck discomfort, occipital headaches, and muscle weakness in the upper arms (Hinkle & Cheever, 2018; Norris, 2019).

 

Figure 3

Swan-Neck Deformity

 (Phoenix119, 2014)

Figure 4

Heberden’s and Bouchard’s nodes

(Lengerke, 2009)

RA has systemic involvement; thus, systemic signs and symptoms are likely present. Patients may experience fatigue, anorexia, weight loss, generalized aching, and stiffness (Hoffman & Sullivan, 2020). RA has been noted to affect the heart, lungs, and eyes. Patients may report a low-grade fever, dry mouth, gum inflammation, shortness of breath, dry eyes, and photosensitivity. The heart and blood vessels may be inflamed, and serum laboratory testing may indicate anemia. The patient may have rheumatoid nodules, which are small lumps surrounding small blood vessels located on or near bony prominences (Arthritis Foundation, 2021; Norris, 2019).

 

Diagnosis

A diagnosis of RA is confirmed using a physical assessment, serum laboratory tests, and imaging (CDC, 2020b). A history and physical evaluation should be performed to assess for pain, disability, joint tenderness, edema, and temperature changes. The joint may have a spongy-like feel due to inflammation and synovial thickening. The serum laboratory tests will include the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and RF. An elevated ESR and CRP indicate the presence of inflammation. The presence of RF confirms a diagnosis of RA; however, RF is absent in 20% of individuals with RA. If the laboratory findings demonstrate a high RF, the patient is likely experiencing systemic effects of RA. The patient’s CBC may show thrombocytosis and anemia due to systemic inflammation (Arthritis Foundation, 2021; Hinkle & Cheever, 2018; Norris, 2019).

Imaging tests include x-ray, ultrasound, or magnetic resonance imaging (MRI) to look for erosions in the bone; bone erosions are a late manifestation of RA. Imaging tests are utilized to assess the effectiveness of RA treatment as well. Synovial fluid may be examined for markers of inflammation; if inflammation is present, the synovial fluid will appear cloudy or yellow (Arthritis Foundation, 2021; Hinkle & Cheever, 2018; Norris, 2019).

 

Treatment/Management

Nonpharmacological 

Patients with RA should be educated on the benefits of rest, physical exercises, and proper body mechanics (Norris, 2019). Patients should also be encouraged to partake in smoking cessation and maintain a healthy weight (CDC, 2020b). Heat and cold therapy have been found to help manage RA symptoms (Arthritis Foundation, 2021). Surgery is a last resort; patients may require a synovectomy, tenosynovectomy, arthrodesis, or arthroplasty (Norris, 2019).

 

Pharmacological 

RA treatment aims to enhance the patient’s mobility by decreasing inflammation and slowing the progression of disability (CDC, 2020b; Scanlon & Sanders, 2019). Early medication initiation is desired due to the potential responsiveness of T-cell-dependent pathways when combatting inflammation (Norris, 2019). Drug classes may include disease-modifying antirheumatic drugs (DMARDs), NSAIDs, corticosteroid medications, and biologic drugs to treat and prevent further inflammation. DMARDs suppress the immune system by combatting pro-inflammatory mediators such as TNF, B-cells, T-cells, and IL-1 (see Table 1). NSAIDs, such as meloxicam (Vivlodex) and naproxen (Naprosyn), and corticosteroids are given to decrease inflammation and pain; however, it is essential to note that they cannot be used concurrently (Norris, 2019). Biologic drugs have been used more frequently over the last decade and effectively treat RA by disrupting the inflammatory cascade. Biologics, such as abatacept (Orencia), are given intravenously by an HCP or patient-administered subcutaneous auto-injector (Bristol Myers Squibb Company, 2021; Hinkle & Cheever, 2018; Hoffman & Sullivan, 2020).

 

Table 1

DMARDS

Nonbiologic DMARDs slow disease progression and/or delay the onset. They have fewer risks and lower costs than biologics.
Methotrexate (Trexall) = first-line treatment	Initial dosing is 7.5 mg administered either orally, intramuscularly, or subcutaneously weekly; it can be given as a single dose or divided doses such as 2.5 mg orally every 12 hours times three doses once weekly; dosing can be increased as tolerated to a maximum dose of 20 mg weekly. Adverse effects include fatigue, dizziness, aphasia, hypotension, blurred vision, stomatitis, diarrhea, GI ulceration, nausea, vomiting, leukopenia, thrombocytopenia, pulmonary embolism, and reduced resistance to infection. Monitor CBC due to effects on hemoglobin, white blood cells (WBCs), red blood cells (RBCs), and platelet counts. Monitor hepatic and renal function due to cirrhosis, hepatic fibrosis, and renal failure risk. Teratogenic, contraindicated in pregnancy, or when planning a pregnancy – both female and male. Administer folic acid (<5 mg/week) to decrease GI and hepatic side effects.
Hydroxychloroquine (Plaquenil)	Typically used in combination with methotrexate (Trexall). Initial dosing is 400 to 600 mg orally as a single dose or divided into two doses; if positive results are observed, the maintenance dose is 200 mg to 400 mg once daily or twice daily in divided doses; the maximum dose is 600 mg/day or 5 mg/kg per day whichever is lower. Adverse effects include seizures, irritability, nightmares, vertigo, dizziness, headaches, fatigue, cardiac arrhythmias, blurred vision, irreversible nystagmus, decreased appetite, diarrhea, nausea, vomiting, and hypoglycemia. Should be taken with milk or food to minimize GI effects. Retinal damage resulting in blindness can occur. This is dosage-related and can occur after the medication is stopped. An ophthalmologic exam should be completed before treatment and then every six months. Educate the patient to report visual changes immediately. Use cautiously in patients with hepatic disease, those with a history of alcohol abuse, or in combination with other hepatoxic drugs. Long-term outcomes are improved by early initiation. The full effect may take 3 to 6 months.
Sulfasalazine (Azulfidine)	Has the specific benefit of slowing joint deterioration. Initial dosing is 0.5 to 1 gram daily to reduce GI effects; if tolerated, the dose can be increased to 2 grams orally daily in 2 divided doses. If unsatisfactory clinical results after 12 weeks, dosing can be increased to 3 grams daily in 2 divided doses. Adverse effects include seizures, dizziness, headaches, depression, nausea, vomiting, abdominal pain, anorexia, stomatitis, dyspepsia, infertility, hemolytic anemia, rash, and pruritus. Should be used cautiously or in reduced doses in patients with impaired renal or hepatic function or those with G6PD deficiency Contraindicated in patients with a sulfa allergy, sensitivity to salicylates, intestinal blockage, or urinary retention. Monitor BMP, liver function, and CBC to detect hepatitis and bone marrow suppression, which can occur but are rare. Therapeutic effects may be seen as early as 4 weeks after initiation of treatment but may take up to 12 weeks.
Leflunomide (Arava)	Initial dosing includes a loading dose of 100 mg orally every 24 hours for 3 days, then 20 mg orally every 24 hours. If 20 mg is not tolerated, the maintenance dose can be decreased to 10 mg daily. Adverse effects include dizziness, headaches, somnolence, malaise, palpitations, varicose veins, blurred vision, retinal hemorrhage, rhinitis, diarrhea, abdominal pain, anorexia, dry mouth, nausea, vomiting, dyspnea, rash, pruritus, severe hypertension, pancytopenia, hepatotoxicity, and Stevens-Johnson syndrome. Elimination of the loading dose may decrease the risk of the patient experiencing adverse side effects, especially in those patients at an increased risk of developing hematologic dysfunction or hepatic toxicity. Monitor liver function monthly, counsel patients to report symptoms of liver failure; contraindicated in patients with liver disease. Contraindicated in patients with severe hepatic impairment. Contraindicated in pregnancy. There is a protocol to clear the drug using cholestyramine which must be implemented before a planned pregnancy for both males and females.
Penicillamine (Depen Titratabs), gold salts, azathioprine (Azasan), cyclosporine (Neoral), minocycline (Minocin), Protein A	Used infrequently as a last resort if other medications are not effective. Have a higher risk of toxicity, thus requiring complete and focused assessment when utilized.
Biologic DMARDs:  These medications interfere with the immunologic response to decrease RA  symptoms. A significant associated cost and risk of infection and/or cancer.
Tissue Necrosis Factor Inhibitors (TNFIs): Interfere with TNF to prevent the release of chemical and immunologic factors that damage joints in RA (and other inflammatory disorders). The medications are each a unique monoclonal antibody that binds to TNF.
Etanercept (Enbrel)	The first-line drug when the use of biologics is indicated. Binds with TNF to prevent it from binding with cell receptors. Dosing is 50 mg subcutaneously once weekly; it can be given as one dose or as 2- 25 mg doses given 3 to 4 days apart. Serious adverse effects include severe allergic reactions, heart failure, cancer (especially lymphoma in younger patients), blood disorders, liver failure, and demyelinating nervous system disorders. Injection site symptoms may last several days. Risks for fungal infections, opportunistic infections, hepatitis B reactivation, and particularly TB – requires TB testing before and monitoring during treatment. Avoid administration with a concurrent disease with infection risk (i.e., diabetes). Live virus vaccines are contraindicated. Withhold 1 week before surgery.
Adalimumab (Humira)	Only indicated for use in adults. Dosing is 40 mg subcutaneously administered every other week. If patients are not taking methotrexate (Trexall), dosing may be increased to 40 mg weekly. Withhold 2 weeks before surgery. See etanercept (Enbrel) for precautions and adverse effects.
Golimumab (Simponi)	Only used in combination with methotrexate (Trexall). Initial dosing is 200 mg subcutaneously, with a second dose of 100 mg administered 2 weeks later, followed by a maintenance dose of 100 mg every 4 weeks. Injection site and upper respiratory tract infections are more common than TNFIs. Withhold before surgery at the recommendation of the HCP. See etanercept (Enbrel) for precautions and adverse effects.
Infliximab (Remicade)	Indicated for use with methotrexate (Trexall) Dosing is 3 mg/kg administered as an intravenous infusion (IV) over 2 hours; administration is repeated at 2 weeks and 6 weeks after the initial dose and then every 8 weeks; if results are inadequate, the dosage can be increased to 10 mg/kg, or administration frequency can be increased to every 4 weeks. Should be administered alone due to incompatibilities with other medications. If an infusion reaction occurs, administration of antihistamines, acetaminophen, and/or corticosteroids, as well as decreasing the infusion rate, can reduce the severity of the reaction. Premedication with these medications may prevent an infusion reaction from occurring. Stop infusion if anaphylaxis occurs. Withhold for 6 – 8 weeks before surgery. See etanercept (Enbrel) for precautions and adverse effects.
Certolizumab pegol (Cimzia)	The initial dosing is 400 mg given in 2 divided doses of 200 mg each, repeated 2 and 4 weeks after the administration of the initial dose; the maintenance dose is 200 mg every other week or 400 mg every 4 weeks. Side effects include upper respiratory tract infections, urinary tract infections, and arthralgia. Withhold 2 weeks before surgery. See etanercept (Enbrel) for precautions and adverse effects.
Non-TNFI biologics
Rituximab (Rituxan)	A monoclonal antibody that reduces B lymphocytes by binding with CD20 on the B cell. Indicated when one or more TNF antagonists have not been effective. Dosing is 1,000 mg IV infusion given 2 weeks apart; based on patient presentation, the administration may need to be repeated every 24 weeks but no closer than every 16 weeks. Infusion reactions can be severe, with onset in 30 to 120 minutes, including angioedema, cardiogenic shock, MI, and bronchospasm. Antihistamine, acetaminophen (Tylenol), and corticosteroids should be given 30 minutes before administration. Corticosteroids, epinephrine, bronchodilators, and oxygen should be immediately available during administration for adverse events. Adverse effects include fever, headache, agitation, hypotension, edema, flushing, rhinitis, oral candidiasis, nausea, vomiting, abdominal pain or bloating, diarrhea, taste perversion, anemia, hyperglycemia, muscle spasms, dyspnea, pruritus, urticaria, and night sweats. Risks include hepatitis B or reactivation of John Cunningham (JC) virus in the brain of patients treated for non-Hodgkin’s lymphoma, causing progressive multifocal leukoencephalopathy.
Abatacept (Orencia)	T-cell activation inhibitor. IV dosing for adults is weight-based: > 100 kg: 1 gram IV administered over 30 minutes, 60 to 100 kg: 75 mg IV administered over 30 minutes For either dose, repeat at 2 and 4 weeks, then continue every 4 weeks. Subcutaneous dosing is 125 mg administered weekly; an IV loading dose following weight-based dosing can be given but is not required; when using an IV loading dose, the first subcutaneous injection must be administered within 24 hours, then once weekly. The first subcutaneous dose replaces the next scheduled IV dose when converting from IV to subcutaneous administration. Adverse effects include headaches, dizziness, pyrexia, dyspepsia, abdominal pain, nausea, and dyspnea. Increases risk for infections (e.g., urinary tract infection (UTI), upper respiratory infection (URI), pneumonia, cellulitis, herpes simplex, and influenza) and cancer. Should not be used with TNF inhibitors or anakinra (Kineret). It may cause a decreased response to all vaccines, and live vaccines are contraindicated.
Tocilizumab (Actemra)	An IL-6 receptor antagonist administered IV. It can be combined with methotrexate (Trexall) but not with TNF inhibitors, other DMARDs, or other immunosuppressant medications. Dosing is 4 mg/kg administered IV over 1 hour every 4 weeks; if needed dose may be increased to 8 mg/kg up to a maximum dose of 800 mg; for patients over 100 kg, the route and dose should be changed to 162 mg administered subcutaneously weekly. Adverse effects include dizziness, headache, peripheral edema, gastritis, diarrhea, abdominal pain, weight gain, and pruritis. Due to the risk of severe infections and colon perforation, it should not be used in patients with diverticulitis or liver damage. Monitor for increased cholesterol, decreased platelets, and decreased neutrophil count. Decreases drug levels and effectiveness of oral contraceptives, warfarin (Coumadin), proton pump inhibitors, and HMG-CoA reductase inhibitors used to lower cholesterol.
Anakinra (Kineret)	Blocks receptors for IL-1. Indicated when one or more non-biologic DMARDs have not been effective. The recommended dose is 100 mg administered subcutaneously once daily at the same time each day. Adverse effects include headache, pyrexia, flu-like symptoms, nausea, vomiting, and arthralgia. It increases the risk of severe infection and is contraindicated if active infection is present. Not to be combined with TNF inhibitors.
Corticosteroids: anti-inflammatory action decreases symptoms until DMARDs are effective and added during flares (Burchum & Rosenthal, 2019)
Prednisone (Deltasone) Prednisolone (Prelone)	Dosing for prednisolone (Prelone) is 5 to 60 mg once daily. Dosing for prednisone (Deltasone) is 5 to 60 mg once daily or in divided doses; when indicated, maintenance dosing can be every other day. The dosage is meant to control symptoms; if decreasing the medication, a 5 to 7-day taper is typical to prevent adverse effects. Adverse effects include euphoria, insomnia, psychotic behavior, vertigo, headaches, edema, blurred vision, peptic ulceration, nausea, vomiting, diarrhea, anemia, hyperglycemia, glucose intolerance, weight gain, tendon rupture, delayed wound healing, osteoporosis, adrenal suppression, and increased vulnerability to infection. Should be administered with food to limit GI effects.

 (Burchum & Rosenthal, 2019; Singh et al., 2016; Woods, 2023)

 

Psoriatic Arthritis

Pathophysiology      

Psoriatic arthritis is a chronic disease in which the immune system attacks the integumentary system (including skin and nails), joints, axial skeleton, and cardiovascular system (Stober, 2021; Veale & Fearon, 2018). Cytokines, particularly interleukin-17, fuel the inflammation in psoriatic arthritis. Activation of interleukin-17 (IL-17) is due to mast cells, γδ T cells, αβ T cells, and innate lymphoid cells in lesioned skin and synovial fluid. IL-17 triggers the inflammatory cells in skin and joints, such as neutrophils, fibroblasts, osteoclasts, and endothelial cells, causing further inflammation and bone remodeling (Blauvelt & Chiricozzi, 2018). The resulting damage contributes to pain, joint destruction, and erosions. Patients may experience one of the five subgroups: asymmetric, spondylitis, symmetric, distal interphalangeal, and mutilans (Hinkle & Cheever, 2018).

 

Risk Factors/Protective Features

Individuals with a genetic predisposition to psoriatic arthritis are at a particularly heightened risk when experiencing significant stress (Stober, 2021). Patients with infections and physical trauma due to T-cell activation are also at a heightened risk for psoriatic arthritis (Norris, 2020). Up to 30% of patients with psoriasis will develop psoriatic arthritis (Ogdie et al., 2020). Many patients are between 30 and 50 at the time of diagnosis; there is no significant difference in gender distribution (Hinkle & Cheever, 2018).

 

Signs and Symptoms

Patients with psoriatic arthritis are likely to experience systemic inflammation. They are likely to have arthritis in their joints, spondylitis, dactylitis (severe inflammation of an entire digit), enthesitis, a form of psoriasis (plaque psoriasis or psoriasis vulgaris), and nail disease. Patients may experience fatigue, back pain, and sleep alterations. Pain may be located in other sites, such as the Achilles tendon, plantar fascia, or tibial tuberosity, due to inflammation at the entheses. In addition, patients may have other conditions with an autoimmune component, such as irritable bowel disease (IBD), obesity, and metabolic diseases (hypertension, NIDDM). Depression and anxiety may also be present (Hinkle & Cheever, 2018; Norris, 2020; Ogdie, 2020).

 

Diagnosis

Psoriatic arthritis is diagnosed based on the patient’s physical assessment, serum laboratory findings, and imaging results. Patients may have an elevated serum uric acid level (Norris, 2020). Hyperuricemia is due to the fast skin changes that cause the breakdown of nucleic acid into uric acid. This may make it difficult to determine if the patient has gout or psoriatic arthritis (Norris, 2019). Like RA, the CRP and ESR are elevated in psoriatic arthritis; however, RF is absent, differentiating between the two conditions (Hoffman & Sullivan, 2020). Imaging tests may demonstrate spondylitis or asymmetrical sacroiliitis (Hinkle & Cheever, 2018).

Treatment/Management

Nonpharmacological 

                The goal of treating psoriatic arthritis is to decrease pain and inflammation and protect the skin and joints. Patients may experience relief from discomfort by participating in PT, occupational therapy (OT), increasing physical activity, weight loss, massage therapy, and smoking cessation. Losing 10% of body weight can significantly reduce inflammation. Patients who desire to swim should be educated on the potential for skin irritation from the chlorine in swimming pools. Patients may try alternative therapies such as acupuncture, heat and cold therapy, and methods to decrease stress. Walking may relieve pain or discomfort (Arthritis Foundation, 2022b; Norris, 2020; Ogdie et al., 2021).

 

Pharmacological 

             Patients with psoriatic arthritis can be prescribed biologics and drugs that impact cytokine function (see Table 1). Cytokine inhibitors can target TNF and IL-23 T-helper-17 cell pathways (Veale & Fearon, 2018). Treatment can also consist of DMARDS (such as methotrexate [Trexall], sulfasalazine [Azulfidine], leflunomide [Arava], and apremilast [Otezla]), a phosphodiesterase-4 inhibitor, and a Janus kinase (JAK)/signal transducer and activator of transcription (STAT) inhibitor. A TNF inhibitor, such as adalimumab (Humira), is only prescribed if other treatments are ineffective. Inhibiting the immune system will lead to fewer skin and joint manifestations of psoriatic arthritis (Norris, 2020; Ogdie et al., 2021). All the above-listed medications follow the dosing guidelines outlined in Table 1 except the following:

• apremilast (Otezla) initial dose is 10 mg orally in the morning on day 1, then 10 mg in the morning and evening on day 2, then 10 mg in the morning and 20 mg in the evening on day 3, then 20 mg in the morning and evening on day 4, then 20 mg in the morning and 30 mg in the evening on day 5, until reaching the maintenance dose of 30 mg in the morning and evening on day 6
• adalimumab (Humira) initial dose is 80 mg subcutaneously, followed by a 40 mg dose 1 week later, then 40 mg every other week; the duration of treatment should not exceed one year (Woods, 2023)

 

Axial Spondyloarthritis

Pathophysiology

Axial spondyloarthritis is an inflammatory disease in the axial skeleton that causes extensive pain and disability (Ritchlin & Adamopoulos, 2021). The condition comprises two subsets: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). AS does not have clear pathogenesis; however, the presence of mononuclear cells points to immune system dysfunction (Norris, 2019, 2020). The inflammation of the spine, including associated pain, contributes to sacroiliitis (inflammation of the sacroiliac joint), an axial spondyloarthritis symptom. Typically, one or both sacroiliac joints are inflamed and painful (Deodhar, 2020). The specific location of the pain is at the entheses, where the ligaments and tendons attach to the bone (American College of Rheumatology, 2021a).

 

Risk Factors/Protective Features

Currently, 1.5 million Americans have axial spondyloarthritis. Patients tend to be younger and male, with an average onset of disease at 28. HLA-B27 is a significant genetic precursor to axial spondyloarthritis. In AS, HLA-B27 has been identified in approximately 90% of patients. In addition, patients of Alaskan, Siberian Eskimo, and Scandinavian Lapp heritage have higher levels of HLFA-B27 than other cultures. In the western parts of the US and Canada, Native American tribes are at greater risk of developing axial spondyloarthritis. Patients at an increased risk of developing axial spondyloarthritis tend to have other systemic inflammatory diseases such as psoriasis, inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), enthesitis (inflammation of the entheses), and uveitis (American College of Rheumatology, 2021a; Deodhar, 2020; Norris, 2019, 2020).

 

Signs and Symptoms

The hallmark patient presentation with axial spondyloarthritis consists of back pain and stiffness for over 3 months (Deodhar, 2020). The back pain tends to occur in the lumbosacral region, buttocks, and hips. Patients with AS report having greater back pain when supine; patients may report prolonged stiffness after rest or sleep. Some patients experience peripheral spondyloarthritis (pain, edema, and stiffness in the extremities). Excessive lumbar lordosis (sway-back) and thoracic kyphosis may be present, particularly as the disease worsens. If the kyphosis is severe, the patient may experience heightened pain levels and balance difficulty contributing to an increased risk of cervical fracture. Patients may also experience fatigue, which can be as debilitating as the pain (American College of Rheumatology, 2021a; Hinkle & Cheever, 2018; Norris, 2019, 2020).

 

Diagnosis

Diagnosing axial spondyloarthritis is based upon criteria established by the Assessment of Spondyloarthritis International Society. The criteria are multi-faceted and include physical assessment findings, patient history, genetic testing, serum, and radiologic findings. The patient must experience back pain for over 3 months, be less than 45 years old, and have the presence of HLA-B27 and sacroiliitis. In addition, they may have another form of arthritis, IBD, psoriasis, uveitis, enthesitis, dactylitis, respond to NSAIDs treatment, a family history, and an elevated CRP or ESR (Deodhar, 2020). Sacroiliitis may be present on MRI or x-rays (American College of Rheumatology, 2021a). Radiologic findings may include a rigid spine, constricted thoracic cavity, degeneration of the hips, and arthritis (Norris, 2020).

 

Treatment/Management

Nonpharmacological 

Patients should be encouraged to participate in fitness programs focusing on back exercises. Swimming has significant benefits as it promotes cardiovascular wellness and muscle tone without stressing joints (Norris, 2020). Patients may benefit from OT and/or PT. When lifestyle changes and medication do not provide relief, patients may require surgical intervention, including a total hip replacement or spinal surgery (American College of Rheumatology, 2021a). At home, patients may benefit from a bed board, a firm mattress, and sleeping in the supine position without a pillow (Norris, 2020).

 

Pharmacological 

NSAIDs may reduce pain and edema. If NSAIDs are ineffective, patients may be prescribed biologics, such as anti-TNF and anti-IL-17 drugs. Anti-TNF drugs include infliximab (Remicade), etanercept (Enbrel), adalimumab (Humira), certolizumab (Cimzia), and golimumab (Simponi). Secukinumab (Cosentyx) is an IL-17 antagonist administered subcutaneously every 4 weeks in the home following patient education on self-administration (Novartis Pharmaceuticals Corporation, 2022). DMARDs, such as sulfasalazine (Azulfidine), may help prevent and treat inflammation and pain. If joint swelling is localized, patients may benefit from corticosteroid injections into joints or tendons (American College of Rheumatology, 2021a). All the above-listed medications follow the dosing guidelines outlined in Table 1 except the following:

• infliximab (Remicade) dosing is 5 mg/kg IV over 2 hours, repeating the dose in 2 to 6 weeks and then every 6 weeks as a maintenance dose
• secukinumab (Cosentyx) when initiating treatment utilizing a loading dose, 150 mg administered subcutaneously every week for 5 weeks, then 150 mg weekly; when initiating treatment without a loading dose, give 150 mg every 4 weeks (Woods, 2023)

 

Gout

Pathophysiology

Patients with gout have high levels of uric acid and urate crystal deposits in the kidneys and joints; typically, the great toe is affected. Patients with primary gout do not have a known cause, whereas, in secondary gout, the cause of the high uric acid levels is known, such as in leukemia, lymphoma treatment, or chronic renal disease. The high uric acid levels increase the production of purines and alter the degradation of nucleic acids. Patients taking thiazide diuretics are at risk of gout due to urate reabsorption in the kidneys, which increases serum levels of uric acid. The disease has four phases: asymptomatic hyperuricemia, acute gout arthritis, intercritical gout, and chronic tophaceous gout (Hinkle & Cheever, 2018; Hoffman & Sullivan, 2020; Norris, 2019).

During the asymptomatic hyperuricemia phase, the patient may have high uric acid levels; however, they may not experience gout pain. In an acute gout arthritis attack, the patient will have a single joint experiencing inflammation and pain as a flare-up. The time between gout flare-ups is known as intercritical gout; if a patient is not treated, their flare-ups are more likely to increase in frequency and severity. Tophaceous gout is the final phase when the uric acid crystals in the joints are large and form tophi, which can promote bone erosion and joint damage (Perez-Ruiz, 2021). The high levels of uric acid cause monosodium crystal deposits in a joint, leading to an inflammatory response when macrophages attempt to phagocytize the monosodium crystals. The more distal the joint, the cooler the temperature; uric acid crystals are less soluble in temperatures less than 37°C. As such, inflammation in the peripheral joints is expected. Micro-tophi formation further promotes the release of leukocytes and the complement cascade. The inflammation damages the cartilage and subchondral bone, resulting in pain. As the frequency of these events increases, so does the risk for chronic arthritis and tophi. A typical gout attack lasts several days to weeks. After 10 years, the patient may experience chronic tophaceous gout; during this time, the patient will have more recurrent, extensive, and painful gout attacks (Hinkle & Cheever, 2018; Hoffman & Sullivan, 2020; Norris, 2019).

 

Risk Factors/Protective Features

Men experience gout more frequently than women. African Americans, Taiwanese, Pacific Islanders, New Zealand Maori, and those living in higher-income nations are at higher risk of developing gout. In addition, patients between the ages of 40 and 60 are at a greater risk of experiencing the clinical manifestations of gout. Approximately 3-6% of men in higher-income nations experience gout. High serum uric acid levels place a patient at risk; hyperuricemia is defined as greater than 7 mg/dL in men and 6 mg/dL in women. More specifically, 1 in 5 with hyperuricemia will experience gout, and the prevalence is increasing. Furthermore, patients with a history of hypertension, diuretic use, chronic renal disease, alcohol use, or a diet high in purines and fructose are at greater risk of developing gout. Patients regularly consuming beer have a greater chance of developing gout than those drinking wine or hard liquor (Clebak et al., 2020; Hinkle & Cheever, 2018; Hoffman & Sullivan, 2020; Norris, 2019, 2020).

 

Signs and Symptoms

Patients may not experience any signs or symptoms during the asymptomatic hyperuricemia phase of gout. From there, pain may be experienced in the distal joints, such as the wrists, fingers, ankles, and heels. The pain may occur at night, following exercise, and after consuming alcohol, medications, or certain foods. The pain and inflammation coincide. The patient will likely experience erythema and edema at the gout attack site; in addition, the patient may experience tenderness on palpation and sensitivity to touch. Asymptomatic periods lasting months to years may separate gout flare-ups. As the frequency of the attacks increases, the patient will progress into the third (intercritical gout) and fourth phase (chronic tophaceous gout; Hoffman & Sullivan, 2020; Norris, 2019).

             Although gout signs and symptoms typically affect the distal joints, the disease has a systemic impact. It correlates with CVD, obesity, metabolic syndrome, hyperlipidemia, alcoholism, and renal insufficiency. Any workup for gout should consider these associated or comorbid conditions (Hoffman & Sullivan, 2020; Norris, 2019).

 

Diagnosis

             Gout should be suspected when serum uric acid levels rise above 6.8 mg/dL. The most definitive diagnostic criteria for gout involves the aspiration of synovial fluid via arthrocentesis to assess for tophaceous deposits. A 24-hour urine collection may be considered to evaluate urate excretion (Clebak et al., 2020; Norris, 2019).

             Imaging tests may further assess the impact on the joint(s). Early imaging tests may not demonstrate any changes to the joint; however, erosions and nodules become visible in time (Hoffman & Sullivan, 2020).

 

Treatment/Management

Nonpharmacological 

Lifestyle changes can enhance the management of gout. More specifically, patient education focusing on avoiding or limiting alcohol, maintaining a healthy weight, smoking cessation, and avoiding purine-rich foods will help patients with gout (Norris, 2019). Purine-rich foods include seafood, alcohol, and red meats (Clebak et al., 2020). If the joint can be temporarily placed in a splint, the patient may experience less pain (Hoffman & Sullivan, 2020).

 

Pharmacological 

Pharmacological management aims to suppress pain and inflammation. Patients should be encouraged to take NSAIDs, such as ibuprofen (Advil) or indomethacin (Indocin), during flare-ups. Indomethacin (Indocin) can be prescribed to individuals older than 15 at a dose of 50 mg orally or rectally 3 times daily. ER formulations should not be used for acute attacks, and treatment should be discontinued as soon as possible after symptoms subside. Oral doses should be taken with food or milk to prevent GI effects. Adverse effects include headaches, dizziness, fatigue, tinnitus, abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting, and peptic ulceration. In addition, patients may be given colchicine (Colcrys) or intra-articular corticosteroids for pain and inflammation. When used to treat gout flare-ups, 1.2 mg should be taken at the first sign of the flare-up, followed by 0.6 mg 1-hour later. Adverse effects include fatigue, headaches, diarrhea, nausea, and vomiting. Long-term medications may be utilized if a patient experiences two or more gout attacks per year or has chronic renal disease, urolithiasis, tophi, chronic gouty arthritis, and joint damage. Allopurinol (Zyloprim) and febuxostat (Uloric) may be used for gout maintenance treatment; allopurinol (Zyloprim) is preferred as febuxostat (Uloric) has a risk of cardiovascular mortality. The initial dosing of allopurinol (Zyloprim) is 100 mg orally daily, increasing by 100 mg every week until serum uric acid levels drop below 6 mg/dL. The maximum dose is 800 mg/day. Once the daily dose increases above 300 mg, the dose should be divided. Adverse effects include nausea, vomiting, abdominal pain, and diarrhea. Allopurinol (Zyloprim) should be administered with food to minimize these effects. Allopurinol (Zyloprim) should not be used to treat a gout exacerbation as it will alter the serum uric acid levels too quickly and may worsen the flare-up. The dosing of febuxostat (Uloric) is 40 mg orally daily; if, after 2 weeks, serum uric acid levels remain above 6 mg/dL, the dose can be increased to 80 mg daily. Adverse effects include dizziness, nausea, and rash. Hepatic function should be monitored at 2 months and again at 4 months after initiating treatment with febuxostat (Uloric; Clebak et al., 2020; Hoffman & Sullivan, 2020; Norris, 2019; Woods, 2023).

 

Juvenile Arthritis

Pathophysiology

Juvenile arthritis consists of juvenile idiopathic arthritis (JIA) and juvenile rheumatoid arthritis. JIA is more common. The cause is unknown; however, it is believed that the immune system attacks and permanently damages the joints. Specifically, TNF-alpha, IL-6, and IL-1 contribute to inflammation in the synovial membrane of the joint (American College of Rheumatology, 2021a; CDC, 2020a; National Institute of Arthritis and Musculoskeletal and Skin Disorders, 2021).

 

Risk Factors/Protective Features

Arthritis impacts 1 in every 1,000 children (American College of Rheumatology, 2021a). Although no specific risk factors have not been outlined, genetics and the environment may contribute to the activation of the immune system against a child’s joint. Juvenile arthritis impacts both male and female children equally and across all ethnicities. The most significant risk factor is having a family member with chronic arthritis and psoriasis (National Institute of Arthritis and Musculoskeletal and Skin Disorders, 2021).             

 

Signs and Symptoms

Juvenile arthritis affects individuals under the age of 16. These individuals may experience periods of remission and exacerbation (i.e., flare-ups). During a flare-up, patients may experience joint pain, edema, erythema, fever, stiffness, rash, fatigue, decreased appetite, and inflammation in the eye. This may cause limping and difficulty with fine motor functions or completing activities of daily living. Patients may experience changes in their skin; they may experience a rash, red patches, or bumps on the skin. The patient may experience changes in their growth, causing one extremity to be shorter than the other. The symptoms are correlated to the joint impacted by the inflammation. Symptoms lasting longer than 6 weeks indicate chronic arthritis (American College of Rheumatology, 2021b; CDC, 2020a; National Institute of Arthritis and Musculoskeletal and Skin Disorders, 2021).

 

Diagnosis

Juvenile arthritis is typically diagnosed through physical assessment, x-rays, and serum laboratory tests, most often conducted by a rheumatologist. After collecting a family and medical history, a physical assessment is performed, including an integumentary and musculoskeletal assessment, gait evaluation, ophthalmic exam (evaluating for uveitis), an abdominal assessment, and lymphatic inspection for edema (CDC, 2020a).

An elevated ESR and CRP indicate inflammation. In addition, autoantibodies are assessed to determine if antibodies are being made to attack the body’s cells and tissues. An antinuclear antibody (ANA) level may be drawn if there is a concern for uveitis; if positive, the patient should follow up with an ophthalmologist. Anti-cyclic citrullinated peptide (CCP) antibodies and RF may be present if a rheumatic component of the arthritis occurs; JIA does not present with positive RF. HLA-B27 may be drawn if enthesitis-related JIA is suspected. A CBC may be ordered to evaluate for infection or anemia; it is not uncommon for patients with juvenile arthritis to experience anemia. A metabolic panel may be ordered to assess renal and liver function (American College of Rheumatology, 2021a; National Institute of Arthritis and Musculoskeletal and Skin Disorders, 2021).

Imaging tests are common to assess for and rule out other conditions. For instance, an x-ray may be ordered to ensure a fracture has not occurred. With JIA, damage to bones will be visible on the x-ray. An ultrasound can visualize the presence of inflammation and excess fluid. MRI scans look at the bones, cartilage, and joints for signs of inflammation and damage (National Institute of Arthritis and Musculoskeletal and Skin Disorders, 2021).

 

Treatment/Management

Nonpharmacological 

Treating a patient with juvenile arthritis requires a holistic approach. The patient may require PT and OT to promote movement, relieve pain, prevent further injuries, and strengthen muscles. The goal is to encourage patients to actively engage in their activities of daily living to their fullest potential. Patients may require care from a mental health practitioner to ensure that they are coping psychologically with the physical and lifestyle changes accompanying a juvenile arthritis diagnosis. Patients should be educated on the benefits of rest and exercise on psychological and physical stress and preventing future pain; swimming is recommended as an activity as it does not stress joints. A splint may help prevent the overuse of the affected joint (National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2021).

             Patients and their families should be encouraged to live life as normally as possible; they should be encouraged to participate in social activities. Summer camps and support groups for children with similar conditions can promote further coping and holistic well-being. If the patient requires accommodations for school, the HCP may complete accommodation forms that align with Section 504 of the Rehabilitation Act. The patient and family should be given information on social services to promote access to care and acquire the necessary resources to ensure a quality of life (American College of Rheumatology, 2021a).

 

Pharmacological 

Patients with juvenile arthritis may experience significant symptom management from a sound medication regimen. The patient may take DMARDs, NSAIDs, biologic response modifiers (which will inhibit TNF-alpha, IL-1, or IL-6 from causing inflammation), and corticosteroids (National Institute of Arthritis and Skin Diseases, 2021). The treatment regimen requires corticosteroids to be given first, followed by DMARDs and biologics due to the potential side effects of these medications. The pediatric patient and their family should be educated about potential adverse effects. A DMARD that may be given is methotrexate (Trexall). Biologic agents include etanercept (Enbrel), adalimumab (Humira), abatacept (Orencia), anakinra (Kineret), canakinumab (Ilaris), and tocilizumab (Actemra; American College of Rheumatology, 2021a). Juvenile arthritis-specific dosing of these medications is as follows:

• methotrexate (Trexall): 10 mg/m² administered either orally, intramuscularly (IM), or subcutaneously once weekly, increasing to 20 to 30 mg/m² if needed
• etanercept (Enbrel):
  • for children weighing ≥ 63 kg, 50 mg subcutaneously once weekly,
  • for children weighing < 63 kg, 0.8 mg/kg subcutaneously once weekly divided into two injections either administered at the same time or 3 to 4 days apart; the maximum dose is 50 mg weekly
• adalimumab (Humira):
  • for children weighing ≥ 30 kg, 40 mg subcutaneously every other week
  • for children weighing 15 to 30 kg, 20 mg subcutaneously every other week
  • for children weighing 10 to 15 kg subcutaneously every other week
• abatacept (Orencia):
  • children that are older than 6 and weigh ≥ 75 kg should follow the adult dosing explained in Table 1 up to a maximum dose of 1,000 mg; for those that weigh < 75 kg, 10 mg/kg administered intravenously over 30 minutes, repeated at 2 weeks and 4 weeks, then every 4 weeks
  • for children older than 2, the dosage is weight-based for those that weigh ≥ 50 kg, 125 mg; for those that weigh 25 to < 49.9 kg, 87.5 mg; for those that weigh 10 to 24.9 kg, 50 mg, administered subcutaneously every week
• anakinra (Kineret): initial dosing is 1 to 2 mg/kg administered subcutaneously; increasing by 0.5 to 1 mg/kg to a maintenance dose of 3 to 4 mg/kg; the maximum dose is 8 mg/kg
• canakinumab (Ilaris): in children that weigh ≥ 7.5 kg, the dosing is 4 mg/kg administered subcutaneously every 4 weeks; the maximum dose is 300 mg
• tocilizumab (Actemra): for children weighing ≥ 30 kg, administer 8 mg/kg; for children weighing < 30 kg, administer 12 mg/kg, IV over 60 minutes once every 2 weeks or 162 mg administered subcutaneously weekly (Woods, 2023)

 

Future Research

Genetic Therapy

             Research is being conducted to examine if molecular profiling may enhance treatment for RA. More specifically, researchers are exploring which genes contribute to resistance to RA treatment, which can lead to more effective therapies (Queen Mary University, 2022).

Aside from RA, genetic profiling can impact numerous forms of arthritis. Scientists are seeking to understand which gene malfunctions lead to arthritis development. This research can help improve gene repair or replacement treatment modalities (The University of Washington Orthopaedics and Sports Medicine, 2022). Beyond treatment, genetic profiling can potentially promote prevention, earlier diagnoses, and treatment of arthritis (Versus Arthritis, 2020).

References

American College of Rheumatology. (2021a). Juvenile arthritis. https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Juvenile-Arthritis

American College of Rheumatology. (2021b). Spondyloarthritis. https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Spondyloarthritis

Arthritis Foundation. (2021). Rheumatoid arthritis. https://www.arthritis.org/diseases/rheumatoid-arthritis

Arthritis Foundation. (2022a). About arthritis. https://www.arthritis.org/about-arthritis

Arthritis Foundation. (2022b). Treatments for psoriatic arthritis. https://www.arthritis.org/health-wellness/treatment/treatment-plan/disease-management/treatment-options-for-psoriatic-arthritis

Blauvelt, A., & Chiricozzi, A. (2018). The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clinical Reviews in Allergy & Immunology, 55. 379-390. https://doi.org/10.1007/s12016-018-8702-3

Burchum, J., & Rosenthal, L. (2019). Lehne’s pharmacology for nursing care (10^th ed.). Elsevier.  

Bristol Myers Squibb Company. (2021). Orencia side effects. https://www.orencia.com/about-orencia/side-effects-of-orencia

Cajas, L. J., Casallas, A., Medina, Y. F., Quintana, G., & Rondón, F. (2019). Pannus and rheumatoid arthritis: Historic and pathophysiological evolution. Revista Colombiana de Reumatología (English Edition), 26(2). https://doi.org/118-128. 10.1016/j.rcreue.2018.10.005

Centers for Disease Control and Prevention. (2020a). Childhood arthritis. https://www.cdc.gov/arthritis/basics/childhood.htm

Centers for Disease Control and Prevention. (2020b). Rheumatoid arthritis. https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html

Centers for Disease Control and Prevention. (2022). Arthritis data and statistics. https://www.cdc.gov/arthritis/data_statistics/index.htm

Chou, R., McDonagh, M. S., Nakamoto, E., Griffin, J. (2011). Analgesics for osteoarthritis: An update of the 2006 comparative effectiveness review. https://www.ncbi.nlm.nih.gov/books/NBK65635/table/introduction.t2/

Clebak, K. T., Morrison, A., & Croad, J. R. (2020) Gout: Rapid evidence review. American Family Physician, 102(9), 533-538. https://www.aafp.org/pubs/afp/issues/2020/1101/p533.html

Deodhar, A. A. (2020). Understanding axial spondyloarthritis; A primer for managed care. American Journal of Managed Care, 25(17). https://www.ajmc.com/view/axial-spondyloarthritis-primer-for-managed-care

Doherty, M., & Abhishek, A. (2021). Osteoarthritis symptoms and diagnosis (beyond the basics). UpToDate. Retrieved November 30, 2022, from https://www.uptodate.com/contents/osteoarthritis-symptoms-and-diagnosis-beyond-the-basics

Hinkle, J. L., & Cheever, K. H. (2018). Brunner & Suddarth’s textbook of medical-surgical nursing (14^th ed). Wolters Kluwer.

Hoffman, J. J., & Sullivan, N. J. (2020). Davis advantage for medical-surgical nursing: Making connections to practice (2^nd ed). F. A. Davis.

Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., Gellar, K., Harvey, W. F., Hawker, G., Herzig, E., Kwoh, C. K., Nelson, A. E., Samuels, J., Scanzello, C., White, D., … Reston, J. (2020). 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis & Rheumatology, 72(2), 220-233. https://doi.org/10.1002/art.41142

Lengerke, J. (2009). Roe-heberden [image]. https://commons.wikimedia.org/wiki/File:Roe-heberden.jpg

National Institute of Arthritis and Musculoskeletal and Skin Disorders. (2021). Juvenile idiopathic arthritis. https://www.niams.nih.gov/health-topics/juvenile-arthritis

Norris, T. (2019). Porth’s pathophysiology: Concepts of altered health states (10^th edition). Wolters Kluwer.

Norris, T. (2020). Porth’s essentials of pathophysiology (5^th ed). Wolters Kluwer.

Novartis Pharmaceuticals Corporation. (2022). Cosentyx Injection Resources. https://www.cosentyx.com/how-to-inject-cosentyx

Ogdie, A., Coates, L. C., & Gladman, D. D. (2020). Treatment guidelines in psoriatic arthritis. Rheumatology. 59(1), i37-i46. https://doi.org/10.1093/rheumatology/kez383

Open Stax College. (2013a). File:907 synovial joints.jpg [Image]. https://commons.wikimedia.org/wiki/File:907_Synovial_Joints.jpg

Open Stax College. (2013b). File:909 types of synovial joints.jpg [Image]. https://commons.wikimedia.org/wiki/File:909_Types_of_Synovial_Joints.jpg

Perez-Ruiz, F. (2021). Gout. UpToDate. Retrieved September 1, 2022, from https://www.uptodate.com/contents/gout-beyond-the-basics

Phoenix119. (2014). Swan neck deformity in a 65-year-old rheumatoid arthritis patient- 2014-05-27 01-49.jpg [Image]. https://commons.wikimedia.org/wiki/File:Swan_neck_deformity_in_a_65_year_old_Rheumatoid_Arthritis_patient-_2014-05-27_01-49.jpg

Queen Mary University. (2022). New study shows genes can predict response to arthritis treatment and paves the way for future drug development. ScienceDaily. https://www.sciencedaily.com/releases/2022/05/220519115305.htm

Ritchlin, C., & Adamopoulos, I. E. (2021). Axial spondyloarthritis: New advances in diagnosis and management. British Medical Journal, 372. https://doi.org/10.1136/bmj.m4447

Scanlon, V. C., & Sanders, T. (2019). Essentials of anatomy and physiology (8^th ed.). F. A. Davis.

Shah, A., Mak, D., Davies, A. M., James, S. L., & Botchu, R. (2019). Musculoskeletal corticosteroid administration: Current concepts. Canadian Association of Radiologists Journal, 70(1), 29-36. https://doi.org/10.1016/j.carj.2018.11.002

Singh, J. A., Saag, K. G., Bridges, S. L., Aki, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shermling, R, H., Curtis, J. R., Furst, D. E., Parks, D., Kavanaugh, A, O’Dell, J., King, C., Leong, A., Matteson, E. L., Schousboe, J.T., … McAlindon, T. (2016). 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.  Arthritis Care & Research, 68(1), 1-25. https://doi.org/10.1002/acr.22783

Stober, C. (2021). Pathogenesis of psoriatic arthritis. Best Practice & Research Clinical Rheumatology, 35(2). https://doi.org/10.1016/j.berh.2021.101694

University of Washington Medicine Orthopaedics and Sports Medicine. (2022). Research on arthritis.  https://orthop.washington.edu/patient-care/articles/arthritis/research-on-arthritis.html

Veale, D. J., & Fearon, U. (2018). The pathogenesis of psoriatic arthritis. The Lancet, 391(10136), 2373-2384. https://doi.org/10.1016/S0140-6736(18)30830-4

Versus Arthritis. (2020). Genetics and genomics help to predict and treat arthritis. https://www.versusarthritis.org/news/2020/march/genetics-and-genomics-how-research-is-helping-us-to-predict-and-treat-arthritis/

Woods, A. D. (2023). Nursing2023 drug handbook. Wolters Kluwer.